Gossamer Bio (NASDAQ:GOSS – Get Free Report)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a research note issued on Monday, Benzinga reports.
GOSS has been the topic of several other reports. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a report on Thursday, August 27th. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a report on Tuesday, July 28th. Finally, Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $256.00.
Get Our Latest Stock Analysis on Gossamer Bio
Gossamer Bio Stock Performance
NASDAQ:GOSS traded down $0.21 during mid-day trading on Monday, reaching $9.39. 30,625 shares of the company’s stock were exchanged, compared to its average volume of 240,078. Gossamer Bio has a one year low of $8.29 and a one year high of $309.60. The firm has a market capitalization of $57.38 million, a PE ratio of -0.17 and a beta of 2.21. The business’s fifty day simple moving average is $11.48 and its two-hundred day simple moving average is $16.16.
Institutional Trading of Gossamer Bio
Several hedge funds have recently modified their holdings of the stock. Rockefeller Capital Management L.P. boosted its holdings in Gossamer Bio by 496.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 60,866 shares of the company’s stock worth $189,000 after acquiring an additional 50,666 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Gossamer Bio by 73.4% in the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock worth $42,000 after acquiring an additional 54,439 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in Gossamer Bio in the first quarter worth about $38,000. ADAR1 Capital Management LLC acquired a new stake in Gossamer Bio in the second quarter worth about $35,000. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Gossamer Bio by 32.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 1,098,914 shares of the company’s stock worth $181,000 after acquiring an additional 270,195 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.
About Gossamer Bio
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.
Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Featured Stories
- Five stocks we like better than Gossamer Bio
- Not All Tech Is Getting Crushed: 5 Names Holding Up Through the AI Sell-Off
- Actively Managed ETFs Are Giving In to the Price War—To the Benefit of Investors
- Valero’s Windfall Quarter Meets Washington’s Push for Cheaper Diesel
- 4 Small-Cap Stocks With Paths to Recovery After the Fed’s September Rate Hike
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
